GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

Get comprehensive insights into the Uncomplicated Urinary Tract Infections (UTIs) pipeline with this 2025 report. It details 4+ companies and 5+ pipeline drugs, covering drug profiles, therapeutic ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance GSK reported core earnings of $1.09 per American depositary share (ADS) for second-quarter 2024, beating the Zacks Consensus Estimate of $1.00.

GSK expects both core operating profit and core EPS to grow in the range of 6-8% including the impact of the share buyback program. R&D is expected to increase at a rate similar to sales growth.

GlaxoSmithKline GSK, +1.18% (GSK), Europe's largest drugmaker, said second-quarter net income slipped to 1.29 billion pounds ($2.6 billion) from 1.33 billion pounds, with revenue rising to 5.87 ...